Objective To study the changes and clinical significance of thromboelastography （TEG） and platelet membrane glycoproteins CD62p and CD63 in primary and recurrent cerebral infarction patients treated with clopidogrel.Methods A total of 103 patients hospitalized for acute cerebral infarction from July 2019 to January 2021 were enrolled in this study. The patients were divided into recurrent cerebral infarction group （n=43） and primary cerebral infarction group （n=60）. The patients were orally administered 75 mg/d clopidogrel. On day 8 after administration， the expression rates of CD62p and CD63 in plasma were determined by flow cytometry， and TEG was performed to measure platelet adenosine diphosphate （ADP） inhibition rate （%）， clot formation kinetics （K）， reaction time （R）， α angle， and maximum amplitude （MA）. The correlations of these parameters withCD62p and CD63 expression rates were analyzed.Results The expression rates of CD62p andCD63 decreased significantly after treatment in both groups （P<0.05）， with significantly greater reductions in the primary group than in the recurrent group （P<0.05）. Compared with the primary group， patients in the recurrent group exhibited significantly lower ADP inhibition rate and K but higher MA （P<0.05）. R was negatively correlated with CD63 expression rate in both groups； ADP inhibition rate was negatively correlated with CD62p expression rate in both groups； ADP inhibition rate was negatively correlated with CD63 expression rate in the recurrent group.Conclusions Patients with recurrent cerebral infarction have higher platelet activity and blood coagulation as compared with patients with primary cerebral infarction after clopidogrel treatment. Measurement of CD62p， CD63， and TEG is of clinical significance.